Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
An Immunopharmacoinformatics Approach in Development of Vaccine and Drug Candidates for West Nile Virus
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
title
An Immunopharmacoinformatics Approach in Development of Vaccine and Drug Candidates for West Nile Virus
Creator
Hossain, Mohammad
Khan,
Sadiq, Abdul
Das, Keshob
Frolov, Andrej
Hashem, Abu
Keya, Chaman
Omar, Taimur
Rakib-Uz-Zaman, S
Salimullah, Md
Singla, Rajeev
Yadav, Dharmendra
source
PMC
abstract
An outbreak of West Nile Virus (WNV) like the recent Ebola can be more epidemic and fatal to public health throughout the world. WNV possesses utmost threat as no vaccine or drug is currently available for its treatment except mosquito control. The current study applied the combined approach of immunoinformatics and pharmacoinformatics to design potential epitope-based vaccines and drug candidates against WNV. By analyzing the whole proteome of 2994 proteins, the WNV envelope glycoprotein was selected as a therapeutic target based on its highest antigenicity. After proper assessment “KSFLVHREW” and “ITPSAPSYT” were found to be the most potential T and B-cell epitopes, respectively. Besides, we have designed and validated four novel drugs from a known WNV inhibitor, AP30451 by adopting computational approaches. Toxicity assessment and drug score confirmed the effectiveness of these drug candidates. This in silico research might greatly facilitate the wet lab experiments to develop vaccine and drug against WNV.
has issue date
2018-07-06
(
xsd:dateTime
)
bibo:doi
10.3389/fchem.2018.00246
bibo:pmid
30035107
has license
cc-by
sha1sum (hex)
2daa7e4d82eecdff82b6ea2bf5f1986b9a9fa8ef
schema:url
https://doi.org/10.3389/fchem.2018.00246
resource representing a document's title
An Immunopharmacoinformatics Approach in Development of Vaccine and Drug Candidates for West Nile Virus
has PubMed Central identifier
PMC6043868
has PubMed identifier
30035107
schema:publication
Front Chem
resource representing a document's body
covid:2daa7e4d82eecdff82b6ea2bf5f1986b9a9fa8ef#body_text
is
schema:about
of
named entity 'BASED'
named entity 'THERAPEUTIC TARGET'
named entity 'APPLIED'
named entity 'ASSESSMENT'
named entity 'ANALYZING'
named entity 'LAB'
named entity 'vaccine'
named entity 'public health'
named entity 'epidemic'
named entity 'WNV'
named entity 'West Nile Virus'
named entity 'glycoprotein'
named entity '5.45'
named entity 'neutralizing antibodies'
named entity 'bioinformatics'
named entity 'malaria'
named entity 'protein'
named entity 'infection'
named entity 'cognitive dysfunction'
named entity 'epitopes'
named entity 'Söding'
named entity 'peptide'
named entity 'epitope'
named entity 'WNV'
named entity 'dengue'
named entity 'vaccine'
named entity 'toxicity'
named entity 'oral bioavailability'
named entity 'permeability'
named entity 'carcinogenic'
named entity '3D protein structure'
named entity 'West Nile virus'
named entity 'MHC-I molecules'
named entity 'vaccine'
named entity 'ADMET'
named entity 'epitopes'
named entity 'MHC-I molecules'
named entity 'Antigenicity'
named entity 'mutation'
named entity 'stereochemistry'
named entity 'Cytotoxic'
named entity 'epitope'
named entity 'molecule'
named entity 'glycoproteins'
named entity 'hydrophilicity'
named entity 'amino acid residues'
named entity 'binding affinity'
named entity 'bioinformatics'
named entity 'epitope'
named entity 'IC50'
named entity 'WNV'
named entity 'vaccine'
named entity 'viral disease'
named entity 'viral disease'
named entity 'conformation'
named entity 'irritative'
named entity 'Bangladesh'
named entity 'binding affinity'
named entity 'Germany'
named entity 'antigenic protein'
named entity 'MHC'
named entity '3D structure'
named entity 'UniProtKB'
named entity 'infection'
named entity 'WNV'
named entity 'PyMol'
named entity 'YASARA'
named entity 'infection'
named entity 'allergenicity'
named entity 'HLA-B'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 8
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software